SAT0272 RITUXIMAB SIGNIFICANTLY DIMINISHES CD86+ B CELLS IN SYSTEMIC SCLEROSIS

Background: Rituximab (RTX) is a monoclonal antibody that targets the CD20 surface marker. This results in a reduction of CD20+ immune cell populations, foremost B cells. B cell depletion via RTX was found to be beneficial for patients suffering from systemic sclerosis (SSc), leading to an improvement of skin fibrosis and autoimmunity (1,2). However, little is known about the influence of RTX on specific B subsets in SSc. Objectives: The purpose of this study was to further characterize the effect of RTX on B cell populations in patients with SSc. Methods: Peripheral blood samples from 37 patients suffering from SSc (mean age: 54 years ± 1.64 SEM, female ratio: 0.78) and 10 age-matched healthy participants were drawn over a sampling period of 2 years. 20 SSc patients in this study group were at the time under RTX treatment and the modified Rodnan Skin score (mRSS) was measured before and after treatment start. The percentage of CD19+/-, CD20+/- lymphatic cells and CD19+CD20+ B cells co-expressing either CD5, CD24, CD27 or CD86 on their surface was done by staining freshly isolated PBMCs. A quantitative flow cytometric bead-based assay (QuantiBRITE PE kit from Becton Dickinson) was used for the estimation of CD19 antibodies bound per cell. All cytometric measurements were performed using a standardized BD LSRFortessa platform. Results: RTX induced a significant decrease in mRSS from 19.7 ± 2.8 to 8.1 ± 1.7 (mean ± SEM; p Conclusion: RTX treatment in SSc might not only be effective by reducing B cells but also by down regulation of the CD86 B cell surface marker on B cells. This would indicate that B cells under RTX treatment are less capable of activating T cells. References [1] Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B Cell Depletion With Rituximab in Patients With Diffuse Cutaneous Systemic Sclerosis. 2009;60(2):578–83. [2] Jordan S, Distler JHW, Maurer B, Huscher D, Laar JM Van, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosiss: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. 2014;1–7. Acknowledgement: Work done in “CBmed” was funded by the Austrian Federal Government within the COMET K1 Centre Program, Land Steiermark and Land Wien. Disclosure of Interests: Barbara Dreo: None declared, Barbara Prietl: None declared, Selina Kofler: None declared, Harald Sourij: None declared, Angelika Lackner: None declared, Florentine Furst-Moazedi: None declared, Monica D’Orazio: None declared, Martin Stradner Speakers bureau: Novartis, Roche, Lilly, BMS,Pfizer, Shire, Winfried Graninger: None declared, Hans-Peter Brezinsek: None declared